Nilogen Oncosystems is dedicated to streamlining and improving drug development in cancer and immuno-oncology. At Nilogen, we appreciate the complexity of cancer and use fresh patient tumor samples with intact tumor immune microenvironment in our preclinical drug testing platforms. This allows us to see the whole picture for a better understanding of the molecular mechanisms of drug sensitivity and resistance. These proprietary and innovative platforms aim to significantly reduce the cost and risk associated with clinical trials. Nilogen’s commitment to testing and customizing cancer drug development is proven and yields unparalleled results for its clients.
Looking for a particular Nilogen Oncosystems employee's phone or email?
The Nilogen Oncosystems annual revenue was $7 million in 2026.
Rikhia Chakraborty is the Chief Scientific Officer of Nilogen Oncosystems.
11 people are employed at Nilogen Oncosystems.
Nilogen Oncosystems is based in Tampa, Florida.
The NAICS codes for Nilogen Oncosystems are [32541, 3254, 541, 54, 325413, 325, 32].
The SIC codes for Nilogen Oncosystems are [873, 87].